The Angel Treatment Pathway

In collaboration with reimbursement expert Eric Faulkner, former global VP of patient value and access at Novartis Gene Therapies, and the Muscular Dystrophy Association, we have developed an initial report to establish a novel pathway to advance treatments for ultra-rare diseases.

This is the first comprehensive approach mapped to date in the U.S. that offers a potential pathway for ultra-rare disease patients to access potentially life-saving therapies. The proposed pathway offers a precedent upon which we can rapidly build and execute this pathway in the U.S.
‍
Complete the form to download the full text of the initial report.